NCT06666114View on ClinicalTrials.gov

Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment

CompletedOBSERVATIONAL
Enrollment

232

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions
Psoriasis (PsO)Psoriatic Arthritis (PsA)
Trial Locations (1)

CEP BR-04.636-900

Novartis, São Paulo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY